{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013199","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.764728+00:00","generated_at":"2026-06-17T00:51:34.850351+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RLY-2608 shows selective PI3Kα inhibition, no Grade 3 hyperglycemia, partial response in breast cancer","bullets":["No Grade 3 hyperglycemia, rash, or diarrhea at target exposures; no dose-limiting toxicities or discontinuations.","Confirmed partial response (RECIST) in metastatic HR+/HER2- breast cancer patient with 12 prior lines of therapy.","Target exposure (~80%+ mutant PI3Kα inhibition) achieved at 400mg BID monotherapy and 600/800mg BID combination.","Nine of 16 breast cancer patients with measurable disease had radiographic tumor reductions; 11 remain on treatment.","Expansion cohorts expected in H2 2023; new first-in-human trial for second PI3Kα inhibitor RLY-5836 initiated April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013199","json":"https://secwatch.observer/filing/0000950170-23-013199.json","markdown":"https://secwatch.observer/filing/0000950170-23-013199.md","text":"https://secwatch.observer/filing/0000950170-23-013199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023013199/0000950170-23-013199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023013199/rlay-20230418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:51:34.850351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}